NIKKEI 225
38,783.27 -116.75 (-0.30%) HANG SENG
18,891.80 +64.45 (+0.34%) CRUDE OIL
78.87 +1.15 (+1.48%) GOLD FUTURES
2,353.80 +19.30 (+0.83%) DOW
39,069.59 +4.29 (+0.01%) Bitcoin GBP
53,503.84 -573.40 (-1.06%)
STOK Aug 2024 12.500 call
| Previous close | 4.1000 |
| Open | 3.9000 |
| Bid | 2.7500 |
| Ask | 4.4000 |
| Strike | 12.50 |
| Expiry date | 2024-08-16 |
| Day's range | 3.9000 - 4.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 19 |
GuruFocus.comInsider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.
Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing
GuruFocus.comStoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
Despite Narrow Miss on EPS, Stoke Therapeutics Advances in Clinical Developments
